Search results
Results from the WOW.Com Content Network
The Seagen bet works in Pfizer's favor in two ways, according to analysts: giving it a new potential blockbuster (or several) with a pipeline built on the buzzy ADC platform and also helping plug ...
(Reuters) -Pfizer said on Tuesday it expects to close its $43 billion deal to buy cancer drugmaker Seagen later this week and plans to create a new oncology division that includes the acquisition ...
At the time of the announcement, Pfizer said Seagen was expected to contribute more than $10 billion in risk-adjusted revenue in 2030. The Seagen purchase came with four approved treatments.
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody -based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs ...
While Pfizer has made a number of acquisitions, its biggest bet is on Seagen. Pfizer wants this to be a transformative acquisition, and it projects Seagen to contribute $10 billion in sales by 2030.
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss reports that Pfizer is in talks to acquire biotech firm Seagen in a $30 billion deal. Pfizer's ( PFE) interest in Seagen ( SGEN ...
1. 2015. Pfizer. Allergan, plc. 160. 206. In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation). However, this deal was cancelled in April 2016 due to new US tax inversion rules. [12][13] Had this transaction been completed, this would have been the largest within this industry.
When it recently bought Seagen, a cancer biotech with advanced therapeutic technology, it was willing to take on $31 billion of debt to make the purchase. Cancer will remain one of Pfizer's new ...